A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Phase 1/2 Unknown 33 enrolled Glycostem Therapeutics BV

NaSingle-groupOpen-labelTreatment

Summary

WiNK is a Phase I/IIa trial to evaluate the safety and efficacy of oNKord® in 33 adults with acute myeloid leukemia (AML) who are in morphologic complete remission with residual measurable disease and who are currently not proceeding to allogeneic hematopoietic stem cell transplantation.

Timeline

Start: 2020-12-08
Primary completion: 2023-04
Completion: 2023-04

Publications

Raimo M, Zavoianu AG, Meijs W, Scholten P, Spanholtz J. Qualification of a flow cytometry-based method for the evaluation of in vitro cytotoxicity of GTA002 natural killer cell therapy. Heliyon. 2024 Jan 17;10(2):e24715. doi: 10.1016/j.heliyon.2024.e24715. eCollection 2024 Jan 30.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	inaleucel	Cell therapy	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Summary

Timeline

Publications

Drugs

Indications